03.24.26 -- The Long Road To U.S. Vaccine Manufacturing

Learn about the development of a serum-free suspension MDCK cell line that serves as an optimal platform for isolating human influenza viruses from clinical samples and producing vaccines at scale.

Uncover how our plant-based peptones support E. coli growth, plasmid yield, and controlled induction, offering a sustainable, animal-free alternative for biopharmaceutical cell culture.

Focusing on quality, the presenters will discuss the importance of adhering to collection protocols and the real-world effects on treatment outcomes.

Advanced plasmid linearization improves transfection efficiency and gene expression, delivering high-purity DNA with rapid turnaround, low endotoxin, and scalable processes for CGT applications.

Discover how surging demand for GLP-1 and other therapeutics is transforming fill/finish capacity and regulatory standards. Learn how CDMOs are adapting to the complex needs of emerging modalities.

Modern sequencing methods offer detection of adventitious and species‑specific viruses. Assimilate how targeted and non‑targeted NGS approaches improve confidence in cell bank characterization.

A cost-effective approach with a comprehensive AAV analytical package holds the potential to advance the application of rAAV in cell and gene therapy for the treatment of human diseases.

Hear how one family, driven by urgency, partnered with AAV experts to develop a treatment for their daughter’s ultra-rare neurodegenerative disorder, NEDAMSS, in just 14 months.

Accelerate the development of high-quality biopharmaceuticals by implementing phase-appropriate, risk-based manufacturing and testing strategies that ensure timely progression.

Choosing the right mRNA manufacturing model can define your success. Uncover how to weigh control, cost, and flexibility to build a strategy that supports innovation and long-term growth.

As the field evolves, the strategies developers choose may prove just as influential as the therapies themselves in determining how quickly innovation reaches patients.